Adjuvant treatment with osimertinib substantially reduces the risk for central nervous system recurrence among patients with resected stage IB–IIIA EGFR-mutated non-small-cell lung cancer, shows an analysis of phase 3 study data.
Patients with completely resected stage IIIA N2 non-small-cell lung cancer do not benefit from postoperative radiotherapy, show the results of the phase 3 Lung ART trial presented at the ESMO Virtual Congress 2020.
The phase 3 CheckMate 9ER trial has demonstrated significantly improved outcomes with the combination of nivolumab and cabozantinib versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma.
Further findings from the TROPHY-U-01 trial indicate that the Trop-2-directed antibody–drug conjugate sacituzumab govitecan has efficacy in heavily pretreated patients with metastatic urothelial cancer.
The final overall survival results of the IMpassion130 trial continue to support the first-line use of atezolizumab plus nab-paclitaxel in PD-L1-expressing patients with metastatic triple-negative breast cancer.
ETOP/IFCT 4-12 STIMULI findings do not support the use of consolidation nivolumab plus ipilimumab for limited-stage small-cell lung cancer patients who have completed chemoradiotherapy and prophylactic cranial irradiation.
People with cancer who receive treatment with immune checkpoint inhibitors may have a reduced risk for a second primary cancer, report French researchers.
Testing for circulating tumor DNA accurately identifies patients with breast cancer suitable for mutation-targeted therapies, results of the phase 2a plasmaMATCH trial show.
Long-term ipsilateral breast tumor recurrence rates are similar whether women are treated with accelerated partial-breast irradiation or whole-breast irradiation, results of the phase 3 APBI-IMRT-Florence trial show.
Men with metastatic castration-resistant prostate cancer who receive ipilimumab after radiotherapy to bone metastases have a significantly better long-term survival rate than those who receive placebo, study findings indicate.
Type 2 diabetes and weight loss are independently associated with an increased risk for pancreatic cancer, and this risk is further elevated when weight loss occurs together with recent-onset diabetes, according to results from a cohort study.
In patients with cancer, the risk for and severity of COVID-19 differs by tumor type, indicates an analysis of data from the UK Coronavirus Cancer Monitoring Project.
In patients with early-stage breast cancer, shorter durations of adjuvant trastuzumab therapy are noninferior to the standard 1-year schedule with regard to disease-free survival, suggests an individual patient data meta-analysis.
Among patients with systemic lupus erythematosus, the risk for cancer may be increased in older patients, men, and those who smoke, suggests an analysis of data from an international cohort.
The BRIGHTLIGHT study has found that adolescent and young adult cancer patients, including those with testicular cancer and other germ cell tumors, present with a wide range and combination of cancer symptoms.
The phase 3 AURA3 trial has failed to demonstrate a significant overall survival gain with second-line osimertinib versus platinum–pemetrexed in patients with advanced non-small-cell lung cancer carrying the EGFR T790M resistance mutation.